SteelPeak Wealth’s ImmunityBio IBRX Stock Holding History

SteelPeak Wealth’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,308	Closed	-$32.7K	–	590
2025 Q3	$32.7K	Sell	13,308 -250	-2%	-$644	﹤0.01%	576
2025 Q2	$35.8K	Buy	13,558 +3,358	+33%	+$9.03K	﹤0.01%	552
2025 Q1	$30.7K	Sell	10,200 -1,000	-9%	-$3.03K	﹤0.01%	562
2024 Q4	$28.7K	Hold	11,200	–	–	﹤0.01%	552
2024 Q3	$41.7K	Hold	11,200	–	–	﹤0.01%	497
2024 Q2	$70.8K	Sell	11,200 -15,000	-57%	-$98.9K	﹤0.01%	512
2024 Q1	$141K	Hold	26,200	–	–	0.01%	443
2023 Q4	$132K	Hold	26,200	–	–	0.01%	410
2023 Q3	$44.3K	Hold	26,200	–	–	﹤0.01%	424
2023 Q2	$72.8K	Buy	26,200 +1,000	+4%	+$2.83K	﹤0.01%	427
2023 Q1	$45.9K	Hold	25,200	–	–	﹤0.01%	376
2022 Q4	$128K	Hold	25,200	–	–	0.01%	386
2022 Q3	$125K	Hold	25,200	–	–	0.01%	377
2022 Q2	$94K	Hold	25,200	–	–	0.01%	383
2022 Q1	$141K	Buy	+25,200	New	+$155K	0.01%	406

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SteelPeak Wealth's IBRX Position: Q4 2025 in Review

SteelPeak Wealth sold out of ImmunityBio (IBRX) in Q4 2025, closing a stake of 13,308 shares — an estimated $32.7K sold.

SteelPeak Wealth first reported a position in IBRX in Q1 2022 and held it in 15 quarters. The position peaked at $141K in Q1 2022. 278 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

SteelPeak Wealth reported no remaining ImmunityBio position as of Q4 2025 after selling out during the quarter.
SteelPeak Wealth sold 13,308 ImmunityBio shares in Q4 2025, an estimated $32.7K.
SteelPeak Wealth first reported a position in ImmunityBio in Q1 2022 and held it in 15 quarters.
SteelPeak Wealth's ImmunityBio position peaked at $141K in Q1 2022.
278 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on SteelPeak Wealth's 13F filing for Q4 2025, filed 20 Jan 2026.